Day One Biopharmaceuticals stock (US23933J1034): cash merger caps journey as Servier deal closes

Day One Biopharmaceuticals has completed its cash merger with Servier, with shareholders set to receive $21.50 per share. The deal removes the oncology specialist from Nasdaq and closes a chapter closely followed by US biotech investors.

Day One Biopharmaceuticals has completed a cash merger with French drugmaker Servier, with common shareholders set to receive $21.50 per share and the company’s stock removed from public trading, according to a corporate actions update from Robinhood published in April 2026 and an SEC filing summarizing the closing on April 23, 2026.Robinhood corporate actions tracker as of 04/24/2026 and StockTitan SEC filings overview as of 04/25/2026.

As of: 05/14/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Day One Biopharmaceuticals
• Sector/industry: Biotechnology / oncology therapeutics
• Headquarters/country: Brisbane, California, United States
• Core markets: Pediatric and adult oncology patients in the US and selected global regions
• Key revenue drivers: Development and commercialization of targeted cancer therapies
• Home exchange/listing venue: Formerly Nasdaq (ticker: DAWN)
• Trading currency: US dollar

Day One Biopharmaceuticals: core business model

Day One Biopharmaceuticals developed targeted cancer therapies with a focus on genetically defined tumors, seeking to address unmet needs in pediatric and adult oncology. Before its acquisition, the company operated as a clinical and early commercial-stage biotech whose value depended heavily on the success of a pipeline centered on precision oncology drug candidates.Day One investor relations overview as of 03/15/2026.

The company’s model combined internal research capabilities with collaborations and licensing agreements to move candidates from discovery into clinical trials. As is common in US biotech, Day One Biopharmaceuticals historically generated limited product revenue while relying on equity financing to fund research and development, making the stock particularly sensitive to trial readouts and capital market conditions, according to its most recent annual and quarterly SEC filings.SEC Form 10-K as of 02/28/2026.

Day One focused on indications where existing treatments were limited, especially for younger patients, aiming to secure regulatory designations such as orphan-drug or breakthrough status where possible. This approach, while targeting smaller populations, can support premium pricing and longer exclusivity periods if clinical data and approvals are ultimately secured, a model seen across the US rare-disease and oncology landscape.FDA oncology approvals overview as of 03/01/2026.

Main revenue and product drivers for Day One Biopharmaceuticals

Prior to the Servier transaction, Day One Biopharmaceuticals’ potential revenue drivers were concentrated in a small number of clinical-stage oncology programs. The company reported research and development expenses significantly exceeding revenues as it advanced these candidates through trials, which is typical for US-listed biotech firms in the high-risk, high-reward segment of the healthcare sector.StockTitan SEC filing summary as of 03/10/2026.

In its quarterly filing for the period ended September 30, 2025, Day One Biopharmaceuticals disclosed key financial metrics that illustrated this profile. The company highlighted research and development spending as its largest cost item and emphasized clinical milestones as the primary future value drivers, according to a Form 8-K filed after results were released and associated commentary from management.StockTitan 8-K summary as of 11/06/2025.

Management communications pointed to potential catalysts such as trial initiations, enrollment updates and regulatory interactions as events that could reshape the company’s risk–reward profile. These factors, combined with broader sentiment toward biotech on Nasdaq, played a role in how the market evaluated Day One Biopharmaceuticals’ equity story before the cash merger removed the stock from public markets.Nasdaq biotech sector overview as of 03/20/2026.

Conclusion

The completion of the Servier cash merger at $21.50 per share marks the end of Day One Biopharmaceuticals’ journey as a standalone Nasdaq-listed oncology player and shifts future value creation to the private sphere. For US investors who held the stock, the transaction translates into a defined cash outcome and closes exposure to the company’s clinical and regulatory milestones. In the broader context, the deal underscores ongoing consolidation in the biotech sector, where larger pharmaceutical groups continue to acquire innovation pipelines from public small-cap developers. While Day One Biopharmaceuticals is no longer available as an independent equity, its path from listing to acquisition remains a reference point for how targeted oncology assets can attract strategic interest.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.